Teladoc price target lowered to $20 from $25 at Barclays

Barclays lowered the firm’s price target on Teladoc to $20 from $25 and keeps an Overweight rating on the shares post the Q1 report. The shares were down post the earnings call on a print that featured a headline beat offset by a Q2 guidance miss and steep second half of the year ramp in BetterHelp revenues, the analyst tells investors in a research note. The firm sees a “show me story” but continues to believe in the inherent long term value of Teladoc’s business.